Origin Biosciences, a subsidiary of BridgeBio Pharma, is a biotechnology company focused treatment for Molybdenum Cofactor Deficiency (MoCD). Origin is led by a team of veteran biotechnology executives. Together with patients and physicians, the company aims to bring a safe, effective treatment for MoCD to market as quickly as possible.
| Website | http://origintx.com |
| Employees | 6 (0 on RocketReach) |
| Founded | 2018 |
| Address | 421 Kipling St, Palo Alto, California, US |
| Technologies | |
| Industry | Biotechnology |
| Keywords | Biotechnology, Rare Diseases, Inborn Errors Of Metabolism, Pharmaceutical, Genetic Disorders, Rare Disease Treatment, Drug Development, Enzyme Therapy, Biopharma, Clinical Trials, Precision Medicine, Therapeutics, Pharmaceutical Research, Biotechnology Research, Gene Therapy, Medical Research, Pediatric Care, New Drug Applications |
| Competitors | Novozymes, Twist Bioscience, Codexis, Inc., Amyris, Synthego Corporation, Geno, Zymergen, Inc., Arzeda, Sestina Bio, LLC. +33 more (view full list) |
Looking for a particular Origin Biosciences employee's phone or email?
Origin Biosciences Questions
Origin Biosciences is based in Palo Alto, California.
Related Companies
G2Crowd Trusted
300K+
Plugin Users
